ELVN Key Statistics, Chart & Performance
The current stock price of ELVN is 20.56 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -19.12%.
ELVN Latest News, Press Relases and Analysis
ELVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About ELVN
Company Profile
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 63 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Company Info
ENLIVEN THERAPEUTICS INC
6200 Lookout Road
Boulder COLORADO US
Employees: 63
Phone: 17206478519
ENLIVEN THERAPEUTICS INC / ELVN FAQ
What does ELVN do?
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. The company is headquartered in Boulder, Colorado and currently employs 63 full-time employees. The company went IPO on 2020-03-12. The company is advancing two parallel lead product candidates, ELVN-001 and ELVN-002, and pursuing several additional research stage opportunities that align with its development approach. Its first product candidate, ELVN-001, is a potent, highly selective, small molecule kinase inhibitor designed to specifically target the breakpoint cluster region-Abelson (BCR-ABL) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia. Its second product candidate, ELVN-002, is a potent, highly selective, central nervous system penetrant and irreversible human epidermal growth factor receptor 2 (HER2) inhibitor with activity against wild type HER2 and various HER2 mutations. ELVN-002 is designed to inhibit wild type HER2 and key mutations of HER2, while sparing wild-type EGFR and avoiding EGFR-related toxicities.
Can you provide the latest stock price for ENLIVEN THERAPEUTICS INC?
The current stock price of ELVN is 20.56 USD. The price increased by 3.58% in the last trading session.
Does ENLIVEN THERAPEUTICS INC pay dividends?
ELVN does not pay a dividend.
How is the ChartMill rating for ENLIVEN THERAPEUTICS INC?
ELVN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ENLIVEN THERAPEUTICS INC (ELVN)?
ENLIVEN THERAPEUTICS INC (ELVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
What is the Short Interest ratio of ENLIVEN THERAPEUTICS INC (ELVN) stock?
The outstanding short interest for ENLIVEN THERAPEUTICS INC (ELVN) is 16.86% of its float.
ELVN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ELVN. When comparing the yearly performance of all stocks, ELVN is a bad performer in the overall market: 72.76% of all stocks are doing better.
ELVN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ELVN. While ELVN has a great health rating, there are worries on its profitability.
ELVN Financial Highlights
Over the last trailing twelve months ELVN reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS increased by 3.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -19.86% | ||
| ROE | -20.48% | ||
| Debt/Equity | 0 |
ELVN Forecast & Estimates
16 analysts have analysed ELVN and the average price target is 41.48 USD. This implies a price increase of 101.75% is expected in the next year compared to the current price of 20.56.